Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from InspireMD ( (NSPR) ) is now available.
InspireMD, Inc., a developer of the CGuard Prime carotid stent system for stroke prevention, reported fourth quarter and full-year 2025 results on March 18, 2026, highlighting strong top-line growth driven by its U.S. launch and expanding international demand. Revenue rose 62% year-over-year in the fourth quarter to $3.1 million, with U.S. sales reaching $0.9 million in only the second quarter of CGuard Prime’s commercial rollout, while gross margin improved to 37.5% on a richer U.S. mix but higher commercial investments pushed the quarterly net loss to $11.8 million.
For full-year 2025, revenue increased 28% to $9.0 million, including $1.4 million from the nascent U.S. business and $7.6 million from international markets, as gross profit nearly doubled and cash and marketable securities rose to $54.2 million by year-end. Operationally, the company completed enrollment in its CGUARDIANS II pivotal trial for use of CGuard Prime in TCAR procedures, submitted a supplemental premarket approval application to the FDA for that indication, and reported supporting over 500 cumulative carotid procedures since launch, moves that underscore its bid to expand its addressable market and strengthen its position in carotid stenting.
The most recent analyst rating on (NSPR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
Spark’s Take on NSPR Stock
According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.
NSPR’s score is held back primarily by very weak financial performance (massive losses and heavy cash burn) and bearish technicals (trading below major moving averages with negative MACD). Offsetting factors include encouraging earnings-call fundamentals—strong Q3 growth, improved gross margin, and constructive Q4 revenue guidance—plus a low-debt balance sheet, but profitability and cash flow remain the key risks.
To see Spark’s full report on NSPR stock, click here.
More about InspireMD
InspireMD, Inc. is a medical device company focused on carotid artery disease and stroke prevention, developing and commercializing the CGuard Prime carotid stent system based on its proprietary MicroNet mesh technology. The company aims to make its products the industry standard for carotid stenting, with a growing commercial presence in the U.S. and key international markets.
Average Trading Volume: 33,018
Technical Sentiment Signal: Sell
Current Market Cap: $75.84M
For an in-depth examination of NSPR stock, go to TipRanks’ Overview page.